ebselen has been researched along with imatinib mesylate in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, LT; Chen, TJ; Chen, YY; Chou, FF; Fang, FM; Huang, HY; Lan, J; Li, CF; Li, SH; Lin, CY; Tai, HC; Yu, SC | 1 |
1 other study(ies) available for ebselen and imatinib mesylate
| Article | Year |
|---|---|
AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis.
Topics: Azoles; Benzamides; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Cyclin D1; Cyclin E; Cyclin-Dependent Kinase 4; Disease-Free Survival; DNA Mutational Analysis; Flow Cytometry; G1 Phase; Gastrointestinal Stromal Tumors; Gene Dosage; Genotype; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Hybridization, Fluorescence; Isoindoles; Multivariate Analysis; Oncogene Proteins; Organoselenium Compounds; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Racemases and Epimerases; RNA Interference; Treatment Outcome; Up-Regulation | 2014 |